Comparing AlloVir (NASDAQ:ALVR) & Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Profitability

This table compares Senti Biosciences and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	-2,692.82%	-74.59%	-48.22%
AlloVir	N/A	-99.73%	-78.86%

Volatility & Risk

Senti Biosciences has a beta of 2.88, meaning that its stock price is 188% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 12.5% of Senti Biosciences shares are held by company insiders. Comparatively, 40.0% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Senti Biosciences and AlloVir’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56 million	6.61	-$71.06 million	($1.60)	-0.23
AlloVir	N/A	N/A	-$190.42 million	($1.84)	-0.43

Senti Biosciences has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Senti Biosciences and AlloVir, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0	0	1	0	3.00
AlloVir	2	3	1	0	1.83

Senti Biosciences currently has a consensus price target of $6.00, suggesting a potential upside of 1,521.62%. AlloVir has a consensus price target of $18.50, suggesting a potential upside of 2,218.30%. Given AlloVir’s higher probable upside, analysts plainly believe AlloVir is more favorable than Senti Biosciences.

Summary

Senti Biosciences beats AlloVir on 8 of the 12 factors compared between the two stocks.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About AlloVir

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.